Risks and side effects of weight management medication: what you need to know
An honest overview of the side effects, risks and safety data of weight management medication. What does the science say? And how do you minimise risks?
Honesty first
At Magistra, we believe you deserve to make an informed choice. That's why we share not only the benefits of personalised weight management, but also the risks. This article is based on published scientific studies and clinical data.
Common side effects
The most commonly reported side effects of weight management medication are gastrointestinal complaints. Clinical studies show:
| Side effect | How common? | Severity |
|---|---|---|
| Nausea | 44% on the drug, 16% on placebo | Mild to moderate, decreases after 2-4 weeks |
| Diarrhoea | 30% on the drug, 16% on placebo | Mild, usually temporary |
| Constipation | 24% on the drug, 11% on placebo | Mild |
| Reduced appetite | 9.8% pooled across our own corpus | Expected effect |
| Headache | 14% on the drug, 10% on placebo | Mild |
Nausea, diarrhoea, constipation and headache are the semaglutide 2.4 mg and placebo columns of Table 3 of the current US Wegovy prescribing information (DailyMed SPL, version 19, effective 18 June 2026; three randomised, placebo-controlled weight-reduction trials, N=2,116 on the drug against N=1,261 on placebo), read from the label on 10 September 2026. That label states no adverse-reaction rate for reduced appetite at all, so that row is our own pooled corpus figure instead — 9.8% from 22 stated rates across 12 distinct studies, read from our live API on 10 September 2026 — which pools all 9 drugs we track and is not a Wegovy number. Other drugs, doses and trials report materially different rates: see magistra.health/en/data-api for our per-source figures, or the full constipation breakdown for what the placebo column does to a headline.
Important: These side effects occur most frequently when starting treatment or when increasing dosage. For most people, they subside within 2-4 weeks.
Serious risks (rare but important)
Clinical studies also report rarer but more serious side effects:
How rare? Serious side effects occurred in 3-7% of participants in clinical studies.
What does the science say about long-term safety?
The most important recent studies:
Honestly: The long-term effects (5-10 years) are not yet fully known. The available data are encouraging, but not complete.
Risks of unsupervised treatment
The real risks arise with unsupervised use:
This is why any medical support you use should come from BIG-registered doctors and licensed compounding pharmacies you arrange directly — Magistra does not broker this itself.
Compounding: an honest caveat
Honest point: Compounded preparations are not clinically tested in the same way as branded products. They use the same active ingredients and European Pharmacopoeia raw materials, but the formulation is individual. This is a trade-off you should make consciously.
The safety guarantees: BIG registration, IGJ inspection, KNMP standards, and medical supervision.
Who is it NOT suitable for?
How do you minimise risks?
Have questions? info@magistra.health
Magistra is a technology platform. This article is informational and does not replace medical advice. Results may vary.
See your own numbers
Our free predictor estimates your side-effect risk and weight trajectory, with the stated rates and distinct sources shown behind every figure. No signup required.
Open the predictorWorking from the data itself? The dated snapshot behind these figures is available as a one-off purchase, alongside the free public API: Data & API.